Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposomal + nituzumab
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Irinotecan liposomal + nituzumab is an investigational combination therapy being studied for the treatment of recurrent or metastatic nasopharyngeal carcinoma after failure of first-line or higher immunotherapy. Irinotecan liposome is a nanoparticle formulation of the topoisomerase I inhibitor irinotecan, designed to improve drug delivery to tumor tissue and reduce toxicity in healthy tissues. Nituzumab is a monoclonal antibody that has shown efficacy in combination with radiotherapy for advanced nasopharyngeal cancer, likely through immune-mediated mechanisms. The combination aims to leverage both cytotoxic and immunotherapeutic effects for improved outcomes in patients who have progressed on standard therapies[1].
- Other names
- irinotecan liposome + nituzumabirinotecan liposomes combined with nituzumab
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan liposomal + nituzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposomal + nituzumab.